[8-K] A SPAC II Acquisition Corp. Unit Reports Material Event

Rhea-AI Filing Summary

ArriVent BioPharma, Inc. (AVBP) – Form 4

On 07/11/2025, Chief Operating Officer Robin LaChapelle exercised stock options with a $2.28 strike price, acquiring 11,153 common shares (2,050 + 2,600 + 6,503). Her direct ownership rises to 135,736 shares. She also reports indirect beneficial ownership of 394,477 shares held by The MAKS Yao Trust, over which she shares voting and investment power but disclaims pecuniary interest.

After the transactions, LaChapelle retains 19,653 unexerced options at the same exercise price, expiring between September 2031 and January 2032. No shares were sold; all transactions are coded “M,” indicating option exercises.

Positive

• 11,153 new shares acquired via option exercise, increasing direct stake to 135,736 shares
• No shares were sold, indicating the insider retained and increased her equity position

Negative

• None.

Insights

Financial Analyst

TL;DR: COO exercised options, added 11,153 AVBP shares; stake now 135,736; no sales – modestly positive.

The filing shows the company’s Chief Operating Officer converting low-priced options into common stock and boosting her direct position by roughly 9%. Lack of share sales points to continued alignment with shareholders, though the transaction size is small relative to float. Remaining unexercised options are minor in potential dilution. Overall impact on valuation is limited, making the event routine but slightly constructive.

Corporate Governance Expert

TL;DR: Routine Form 4; insider boosts stake, trust disclosure clear; governance impact neutral-positive.

The Form 4 is timely and complete under Section 16, detailing option exercises and updated direct/indirect holdings. The disclaimer of pecuniary interest in the trust mitigates conflict-of-interest concerns. No late filings, 10b5-1 references, or sales appear, signalling sound governance practices. The disclosure slightly enhances transparency but is not materially transformative.

false 0001876716 00-0000000 0001876716 2025-07-14 2025-07-14 0001876716 ASCBF:UnitsEachConsistingOfOneClassOrdinaryShareWithNoParValueOnehalfOfOneRedeemableWarrantAndOneRightToreceiveOnetenthOfOneClassOrdinaryShareMember 2025-07-14 2025-07-14 0001876716 ASCBF:ClassOrdinarySharesIncludedAsPartOfUnitsMember 2025-07-14 2025-07-14 0001876716 ASCBF:RightsIncludedAsPartOfUnitsMember 2025-07-14 2025-07-14 0001876716 ASCBF:WarrantsIncludedAsPartOfUnitsMember 2025-07-14 2025-07-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

July 14, 2025

Date of Report (Date of earliest event reported)

ASPAC II Acquisition Corp.

(Exact Name of Registrant as Specified in its Charter)

British Virgin Islands		001-41372		N/A
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

289 Beach Road #03-01 Singapore 199552		N/A
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: +65 6818 5796

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act:

Title of each class		Trading Symbol
Units, each consisting of one Class A ordinary share, with no par value, one-half of one redeemable warrant and one right to receive one-tenth of one Class A ordinary share		ASUUF
Class A ordinary shares included as part of the units		ASCBF
Rights included as part of the units		ASCRF
Warrants included as part of the units		ASCWF

☒ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 1.01 Entry into a Material Definitive Agreement.

Issuance of Promissory Note

On July 14, 2025, A SPAC II Acquisition Corp. (the “Company”) issued an unsecured promissory note in the aggregate principal amount of $152,000 (the “Note”) to A SPAC II (Holdings) Corp., the Company’s sponsor (the “Sponsor”). The Note shall be payable no later than the date on which the Company consummates an initial business combination. Such Note is convertible into warrants having the same terms and conditions as the public warrants, at the price of $1.00 per warrant, at the option of the Sponsor. The Note does not bear interest.

The proceeds of the Note will be used by the Company to pay various expenses of the Company and for working capital purposes.

The foregoing description of the Note is qualified in its entirety by reference to the full text of the Note, a copy of which is filed with this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference.

Item 9.01 Exhibits 

Exhibit No.		Description
10.1		Promissory Note, dated July 14, 2025, issued to the Sponsor.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	A SPAC II ACQUISITION CORP.
Dated: July 15, 2025
	By:	/s/ Serena Shie
		Name:	Serena Shie
		Title:	Chief Executive Officer

2

FAQ

How many ArriVent BioPharma (AVBP) shares did COO Robin LaChapelle acquire?

11,153 common shares were acquired on 07/11/2025 via option exercises.

What was the exercise price of the stock options in the AVBP Form 4?

Each option was exercised at a $2.28 strike price.

What is Robin LaChapelle's total direct AVBP shareholding after the transactions?

Her direct ownership increased to 135,736 common shares.

How many AVBP shares are held indirectly through The MAKS Yao Trust?

The trust holds 394,477 shares; the reporting person disclaims pecuniary interest.

Does the Form 4 report any sale of AVBP shares?

No; all reported transactions were option exercises coded “M,” with no shares sold.